-
公开(公告)号：US20230128444A1
公开(公告)日：2023-04-27
申请号：US17936062
申请日：2022-09-28
Applicant: AMGEN INC.
Inventor： Hailing HSU , Ming ZHANG , Gunasekaran KANNAN , Frederick W. JACOBSEN , Wayne H. TSUJI
Abstract: Described herein are bispecific proteins specific for BAFF and B7RP1, nucleic acids encoding such proteins, methods of making such proteins, and uses for such proteins.
-
公开(公告)号：US20230265145A1
公开(公告)日：2023-08-24
申请号：US18001913
申请日：2021-06-25
Applicant: AMGEN INC.
Inventor： Hailing HSU , Ian FOLTZ , Marissa MOCK , Victor Mitch LUNA , Ming ZHANG , Sharon Lynn WANNBERG , Gamze Ozlem CAMDERE TAPIA , Timothy Patrick RILEY
CPC classification number: C07K14/5428 , C07K16/2803 , A61K38/00 , C07K2319/00
Abstract: Abstract: The present disclosure relates, in general, to muteins of IL-10 that are stable as monomers, antigen binding proteins that bind to TREM-1, and antigen binding proteins comprising IL-10 muteins and antigen binding moieties, e.g., anti-TREM-1 antibodies, and compositions thereof. The disclosure also provides methods of treating inflammatory disease, such as inflammatory bowel disease or ulcerative colitis, using the compositions.
-
公开(公告)号：US20220323545A1
公开(公告)日：2022-10-13
申请号：US17640177
申请日：2020-09-02
Applicant: AMGEN INC.
Inventor： Hailing HSU
Abstract: This invention provides compositions comprising a protein and an absorption enhancer, methods for treating inflammatory disorders, such as irritable bowel disease (IBD) comprising administering same, and methods for oral, intra-rectal, or other gut-related administration of a protein with an enzymatic activity, comprising orally, intra-rectally, or other gut-related administering same.
-
Patent Agency Ranking
公开(公告)号：US20160176926A1
公开(公告)日：2016-06-23
申请号：US14860381
申请日：2015-09-21
Applicant: AMGEN INC.
Inventor： Hosung MIN , Hailing HSU , Fei XIONG
CPC classification number: C07K7/08 , A61K38/00 , A61K38/10 , C07K1/047 , C07K14/001 , C07K14/4702 , C07K14/7151 , C07K16/241 , C07K2319/30 , C07K2319/74 , C12N15/1037 , C40B40/02
Abstract: The present invention concerns therapeutic agents that modulate the activity of TALL-1. In accordance with the present invention, modulators of TALL-1 may comprise an amino acid sequence Dz2Lz4 wherein z2 is an amino acid residue and z4 is threonyl or isoleucyl. Exemplary molecules comprise a sequence of the formulae (SEQ. ID. NO: 100) a1a2a3CDa6La8a9a10Ca12a13a14, (SEQ. ID. NO: 104) b1b2b3Cb6Db8Lb10b11b12b13b14Cb16b17b18 (SEQ. ID. NO: 105) c1c2c3Cc5Dc7Lc9c10c11c12c13c14Cc16c17c18 (SEQ. ID. NO: 106) d1d2d3Cd5d6d7WDd10Ld13d14d15Ld16d17d18 (SEQ. ID. NO: 107) e1e2e3Ce5e6e7De9Le11Ke13ce15e16e17e18 (SEQ. ID NO: 109) f1f2f3Kf5Df7Lf9f10Qf12f13f14 wherein the substituents are as defined in the specification. The invention further comprises compositions of matter of the formula (X1)a—V1—(X2)b wherein V1 is a vehicle that is covalently attached to one or more of the above TALL-1 modulating compositions of matter. The vehicle and the TALL-1 modulating composition of matter may be linked through the N- or C-terminus of the TALL-1 modulating portion. The preferred vehicle is an Fc domain, and the preferred Fc domain is an IgG Fc domain.
Abstract translation: 本发明涉及调节TALL-1活性的治疗剂。 根据本发明，TALL-1的调节剂可以包含氨基酸序列Dz2Lz4，其中z2是氨基酸残基，z4是苏氨酰基或异亮氨酰基。 示例性分子包括下式的一个序列（SEQ。ID NO：100）a1a2a3CDa6La8a9a10Ca12a13a14，（SEQ ID NO：104）b1b2b3Cb6Db8Lb10b11b12b13b14Cb16b17b18（SEQ ID。NO：105）c1c2c3Cc5Dc7Lc9c10c11c12c13c14Cc16c17c18（SEQ ID。NO：106）d1d2d3Cd5d6d7WDd10Ld13d14d15Ld16d17d18（ SEQ ID NO：107）e1e2e3Ce5e6e7De9Le11Ke13ce15e16e17e18（SEQ ID NO：109）f1f2f3Kf5Df7Lf9f10Qf12f13f14其中取代基如说明书中所定义。 本发明还包括式（X1）a-V1-（X2）b的物质的组合物，其中V1是共价连接到一种或多种上述TALL-1调节组合物的载体。 载体和TALL-1调节组合物可以通过TALL-1调节部分的N末端或C末端连接。 优选的载体是Fc结构域，优选的Fc结构域是IgG Fc结构域。
-
公开(公告)号：US20220213226A1
公开(公告)日：2022-07-07
申请号：US17379968
申请日：2021-07-19
Applicant: AMGEN INC.
Inventor： Hailing HSU , Gunasekaran KANNAN , Kenneth W. WALKER , Michelle HORTTER , Edward J. BELOUSKI
IPC: C07K16/46 , C07K16/24 , C07K16/28 , A61K39/395
Abstract: The present invention concerns antigen binding proteins that bind TL1A, including bispecific antigen binding proteins (e.g., antibodies) to TL1A and TNF-α. Such bispecific antibodies can be in a tetrameric immunoglobulin format, in which one heavy chain-light chain pair of the antibody is directed to TL1A and the other to TNF-α. The bispecific antigen binding proteins may also be comprised in an IgG-scFv fusion, in which a conventional tetrameric antibody directed to one antigen is fused to a pair of single chain Fv units directed to the other. The bispecific antigen binding protein may also be comprised in an IgG-Fab fusion, in which a Fab molecule that binds to one antigen is fused to each heavy chain of a conventional tetrameric antibody directed to the other antigen. The invention further relates to uses of the anti-TL1A binding proteins and anti-TL1A/anti-TNF-α antigen binding proteins, and pharmaceutical formulations thereof.
-
公开(公告)号：US20190119407A1
公开(公告)日：2019-04-25
申请号：US16062096
申请日：2016-12-14
Applicant: AMGEN INC.
Inventor： Hailing HSU , Gunasekaran KANNAN , Kenneth W. WALKER , Michelle HORTTER , Edward J. BELOUSKI
Abstract: The present invention concerns antigen binding proteins that bind TL1A, including bispecific antigen binding proteins (e.g., antibodies) to TL1A and TNF-α. Such bispecific antibodies can be in a tetrameric immunoglobulin format, in which one heavy chain-light chain pair of the antibody is directed to TL1A and the other to TNF-α. The bispecific antigen binding proteins may also be comprised in an IgG-scFv fusion, in which a conventional tetrameric antibody directed to one antigen is fused to a pair of single chain Fv units directed to the other. The bispecific antigen binding protein may also be comprised in an IgG-Fab fusion, in which a Fab molecule that binds to one antigen is fused to each heavy chain of a conventional tetrameric antibody directed to the other antigen. The invention further relates to uses of the anti-TL1A binding proteins and anti-TL1A/anti-TNF-α antigen binding proteins, and pharmaceutical formulations thereof.
-
公开(公告)号：US20140302036A1
公开(公告)日：2014-10-09
申请号：US14203123
申请日：2014-03-10
Applicant: Amgen Inc.
Inventor： Hailing HSU , Ming ZHANG , Gunasekaran KANNAN , Frederick W. JACOBSEN , Wayne TSUJI
IPC: C07K16/24 , C07K16/46 , A61K45/06 , C07K16/22 , A61K39/395
CPC classification number: C07K16/468 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/2827 , C07K16/2875 , C07K2317/31 , C07K2317/524 , C07K2317/526 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/94 , C07K2318/10 , C07K2319/70
Abstract: Described herein are bispecific proteins specific for BAFF and B7RP1, nucleic acids encoding such proteins, methods of making such proteins, and uses for such proteins.
Abstract translation: 本文描述了对BAFF和B7RP1特异性的双特异性蛋白质，编码这种蛋白质的核酸，制备此类蛋白质的方法以及这些蛋白质的用途。
-
公开(公告)号：US20140234334A1
公开(公告)日：2014-08-21
申请号：US13938141
申请日：2013-07-09
Applicant: AMGEN INC.
Inventor： Hosung MIN , Hailing HSU , Fei XIONG
CPC classification number: C07K7/08 , A61K38/00 , A61K38/10 , C07K1/047 , C07K14/001 , C07K14/4702 , C07K14/7151 , C07K16/241 , C07K2319/30 , C07K2319/74 , C12N15/1037 , C40B40/02
Abstract: The present invention concerns therapeutic agents that modulate the activity of TALL-1. In accordance with the present invention, modulators of TALL-1 may comprise an amino acid sequence Dz2Lz4 wherein z2 is an amino acid residue and z4 is threonyl or isoleucyl. Exemplary molecules comprise a sequence of the formulae (SEQ. ID. NO: 100) a1a2a3CDa6La8a9a10Ca12a13a14, (SEQ. ID. NO: 104) b1b2b3Cb5b6Db8Lb10b11b12b13b14Cb16b17b18 (SEQ. ID. NO: 105) c1c2c3Cc5Dc7Lc9c10c11c12c13c14Cc16c17c18 (SEQ. ID. NO: 106) d1d2d3Cd5d6d7WDd10Ld13d14d15Ld16d17d18 (SEQ. ID. NO: 107) e1e2e3Ce5e6e7De9Le11Ke13Ce15e16e17e18 (SEQ. ID NO: 109) f1f2f3Kf5Df7Lf9f10Qf12f13f14 wherein the substituents are as defined in the specification. The invention further comprises compositions of matter of the formula (X1)a—V1—(X2)b wherein V1 is a vehicle that is covalently attached to one or more of the above TALL-1 modulating compositions of matter. The vehicle and the TALL-1 modulating composition of matter may be linked through the N- or C-terminus of the TALL-1 modulating portion. The preferred vehicle is an Fc domain, and the preferred Fc domain is an IgG Fc domain.
Abstract translation: 本发明涉及调节TALL-1活性的治疗剂。 根据本发明，TALL-1的调节剂可以包含氨基酸序列Dz2Lz4，其中z2是氨基酸残基，z4是苏氨酰基或异亮氨酰基。 示例性分子包括下式的一个序列（SEQ。ID NO：100）a1a2a3CDa6La8a9a10Ca12a13a14，（SEQ ID NO：104）b1b2b3Cb5b6Db8Lb10b11b12b13b14Cb16b17b18（SEQ ID。NO：105）c1c2c3Cc5Dc7Lc9c10c11c12c13c14Cc16c17c18（SEQ ID。NO：106）d1d2d3Cd5d6d7WDd10Ld13d14d15Ld16d17d18（ SEQ ID NO：107）e1e2e3Ce5e6e7De9Le11Ke13Ce15e16e17e18（SEQ ID NO：109）f1f2f3Kf5Df7Lf9f10Qf12f13f14其中取代基如说明书中所定义。 本发明还包括式（X1）a-V1-（X2）b的物质的组合物，其中V1是共价连接到一种或多种上述TALL-1调节组合物的载体。 载体和TALL-1调节组合物可以通过TALL-1调节部分的N末端或C末端连接。 优选的载体是Fc结构域，优选的Fc结构域是IgG Fc结构域。
-
-
-
-
-
-
-
Search Results
8
records
(took 0.025 seconds)
